Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2022-12-01 Epub Date: 2022-07-06 DOI:10.1159/000525838

Wonguen Jung, Kyubo Kim, Byung-In Moon

{"title":"Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer.","authors":"Wonguen Jung, Kyubo Kim, Byung-In Moon","doi":"10.1159/000525838","DOIUrl":null,"url":null,"abstract":"Purpose: The purpose of this study was to evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer according to the risk group using EndoPredict (EP) score.Patients and methods: Between 2015 and 2019, 207 patients with ER+/HER2- pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. The EPclin score, which combines the molecular EP score with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.3.Results: There were 154 and 53 patients in the EPclin low- and high-risk groups, respectively. Forty-one patients (81.1%) of the high-risk group received adjuvant chemotherapy, while only 1 (0.6%) of the low-risk group did. With a median follow-up of 54.1 months (range 8.2-76.6), the 5-year disease-free survival rates of low- and high-risk groups were 100% and 88.9%, respectively (p < 0.001).Conclusions: The EPclin score was associated with recurrences in ER+/HER2- early breast cancer.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801398/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000525838","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose: The purpose of this study was to evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer according to the risk group using EndoPredict (EP) score.

Patients and methods: Between 2015 and 2019, 207 patients with ER+/HER2- pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. The EPclin score, which combines the molecular EP score with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.3.

Results: There were 154 and 53 patients in the EPclin low- and high-risk groups, respectively. Forty-one patients (81.1%) of the high-risk group received adjuvant chemotherapy, while only 1 (0.6%) of the low-risk group did. With a median follow-up of 54.1 months (range 8.2-76.6), the 5-year disease-free survival rates of low- and high-risk groups were 100% and 88.9%, respectively (p < 0.001).

Conclusions: The EPclin score was associated with recurrences in ER+/HER2- early breast cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

根据er2阳性、her2阴性早期乳腺癌endpredict评分的治疗结果

目的:本研究的目的是使用endopdict (EP)评分来评估雌激素受体阳性/人表皮生长因子受体2阴性(ER+/HER2-)乳腺癌的治疗效果。患者和方法:在2015年至2019年期间，共收集了207例ER+/HER2- pN0-N1早期乳腺癌患者，这些患者接受了手术、EP检查和辅助放疗。将分子EP评分与淋巴结状态、肿瘤大小相结合，计算EPclin评分，并按截断值3.3将患者分为EPclin低、高危组。结果:EPclin低、高危组分别为154例和53例。高危组41例(81.1%)接受了辅助化疗，低危组只有1例(0.6%)接受了辅助化疗。中位随访54.1个月(范围8.2 ~ 76.6)，低危组和高危组5年无病生存率分别为100%和88.9% (p < 0.001)。结论:EPclin评分与ER+/HER2-早期乳腺癌的复发相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊